Skip to main content

Advertisement

SpringerLink
Log in

Should high hTg levels in the absence of iodine uptake be treated?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lind P. Should high hTg levels in the absence of iodine uptake be treated? For. Eur J Nucl Med Mol Imaging 2003; 30:157–160.

    Article  PubMed  Google Scholar 

  2. Biermann M, Schober O. Should high hTg levels in the absence of iodine uptake be treated? Against. Eur J Nucl Med Mol Imaging 2003; 30:160–163.

    Article  CAS  PubMed  Google Scholar 

  3. Britton KE, Granowska M. Radioimmunoscintigraphy in tumour identification. Cancer Surv 1987; 6:247–267.

    Google Scholar 

  4. Britton KE, Foley RR, Siddiqi A, et al. I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when I-131 tracer is negative but raised. Eur J Nucl Med 1999; 26:1013.

    Google Scholar 

  5. Siddiqui A, Foley RR, Britton KE, et al. The role of I-123 diagnostic maging in the follow up of patients with differentiated thyroid carcinoma as compared to I-131-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol 2001; 55:515–521.

    Google Scholar 

  6. Maxon HR III, Thomas SR, Washburne LC, et al. High activity I-123 for the diagnostic evaluation of patients with thyroid cancer. J Nucl Med 1993; 25:242–246.

    Google Scholar 

  7. Gulzar Z, Jana S, Young I, et al. Neck and whole-body scanning with a 5 mCi dose of I-123 as diagnostic tracer in patients with well differentiated thyroid cancer. Endocrine Practice 2001; 7:244–249.

    Google Scholar 

  8. Kalinyak JE. I-123 as a diagnostic tracer in the management of thyroid cancer. Nucl Med Commun 2002; 23:509–511.

    Google Scholar 

  9. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of I-131 after 185 MBq I-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25:242–246.

    Google Scholar 

  10. Sarkar SD, Kalapparabath TP, Palestro CJ. Comparison of I-123 and I-131 for whole body imaging and thyroid cancer. J Nucl Med 2002; 43:632–634.

    Google Scholar 

  11. Shankar LK, Yamamoto AJ, Alavi IA, Mandel SJ. Comparison of I-123 scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 2002; 43:72–76.

    Google Scholar 

  12. Park HM. Invited commentary: I-123 almost a designer radioiodine for thyroid scanning. J Nucl Med 2002; 43:77–78.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, St Bartholomew's Hospital, Queen Elizabeth II Wing, 62 Bartholomew's Close, West Smithfield, London, EC1A 7BE, UK

    K. E. Britton & R. R. Foley

  2. Department of Endocrinology, St Bartholomew's Hospital, London, UK

    S. L. Chew

Authors
  1. K. E. Britton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. R. Foley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. L. Chew
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. E. Britton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Britton, K.E., Foley, R.R. & Chew, S.L. Should high hTg levels in the absence of iodine uptake be treated?. Eur J Nucl Med Mol Imaging 30, 794–795 (2003). https://doi.org/10.1007/s00259-003-1139-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1139-8

Keywords

Search

Navigation